PDGFRβ is an essential therapeutic target for BRCA1-deficient mammary tumors.

Feng BaiShiqin LiuXiong LiuDaniel P HollernAlexandria ScottChuying WangLihan ZhangCheng FanLi FuCharles M PerouWei-Guo ZhuXin-Hai Pei

Published in: Breast cancer research : BCR (2021)

Our work offers the first genetic and biochemical evidence that PDGFRβ-PKCα signaling is repressed by BRCA1, which establishes PDGFRβ-PKCα signaling as a therapeutic target for BRCA1-deficient breast cancers.

Keyphrases

breast cancer risk
genome wide
gene expression
young adults
childhood cancer